APA (7th ed.) Citation

LS, G., LD, T., R, G., GR, S., J, W., P, G., . . . MT, S. (2021). Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. The Prostate, 81(7), 418. https://doi.org/10.1002/pros.24118

Chicago Style (17th ed.) Citation

LS, Graham, et al. "Targeting Backdoor Androgen Synthesis Through AKR1C3 Inhibition: A Presurgical Hormonal Ablative Neoadjuvant Trial in High-risk Localized Prostate Cancer." The Prostate 81, no. 7 (2021): 418. https://doi.org/10.1002/pros.24118.

MLA (9th ed.) Citation

LS, Graham, et al. "Targeting Backdoor Androgen Synthesis Through AKR1C3 Inhibition: A Presurgical Hormonal Ablative Neoadjuvant Trial in High-risk Localized Prostate Cancer." The Prostate, vol. 81, no. 7, 2021, p. 418, https://doi.org/10.1002/pros.24118.